NDUFAB1 and cancer: The ACP-based surface engineering system offers a promising solution to the major limitations of current cancer immunotherapy, particularly for solid tumors characterized by antigenic heterogeneity and immunosuppressive microenvironments, by enabling rapid, reversible, and multi-antigen functionalization without genetic manipulation.